US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Mereo BioPharma Group plc
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
August 11, 2026
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
August 11, 2026
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 12, 2026
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
March 19, 2026
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Provides Corporate Update
January 12, 2026
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
November 10, 2025
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
August 12, 2025
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
May 13, 2025
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
March 26, 2025
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
March 05, 2025
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Provides Update on Lead Clinical Programs
January 12, 2025
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 14, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
September 12, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 13, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
June 14, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
May 30, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
January 08, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
RARE
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
October 23, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
September 07, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
May 23, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 08, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Tickers
MREO
